Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and … (NCT02602600) | Clinical Trial Compass
CompletedPhase 4
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
Denmark33 participantsStarted 2015-11-19
Plain-language summary
The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary artery stenosis.
Who can participate
Age range40 Years – 75 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).
* Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).
* Referred for ischemic heart disease (IHD) assessment with no significant coronary stenosis (\>50%) at coronary angiography or CT-angiography
* Impaired CFR assessed by echo Doppler flow (defined ratio≤2,5).
* BMI≥25kg/m2
Exclusion Criteria:
* Allergy to dipyridamole, theophyllamine or liraglutide
* Previous myocardial infarction or revascularization
* No episodes of chest pain within 6 months before inclusion
* Diabetes (reported, noted in journal or patient on antidiabetic medication)
* Other causes of chest discomfort deemed highly likely
* Left ventricular ejection fraction \<45
* Significant valvular disease
* Congenital heart disease
* severe co-morbidity with limited life-expectancy\< 1 year
* Severe asthma
* Severe chronic obstructive pulmonary disease
* Pregnancy (pregnancy test will be done at inclusion)
* No use of contraception although in child-bearing age. A woman is regarded fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. The birth control methods considered safe and effective includes combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intrava…
What they're measuring
1
Change from baseline in Coronary Flow Reserve
Timeframe: Assessed at baseline, week 4 and week 18
2
Change from baseline in Angina Symptoms
Timeframe: Assessed at baseline, week 4 and week 18